Dermatophyte InfectionNCT06729216
Fungal Resistance in Dermatophyte Infection
An observational study of Dermatophyte Infection, run by Cairo University.
Trial summary
The aim of the study is to compare the efficiency of broth microdilution versus disk diffusion method for antifungal drug susceptibility testing of the most used drugs in dermatophytosis treatment. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Dermatophyte Infection
- What is being tested?
- Antifungal susceptibility testing (AFST)
- How many people
- 42 participants
- Where
- No sites listed yet
- Study dates
- 1 Jun 2025to 1 Aug 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: Patients with dermatophytic skin infection
Who may be able to join
- Patients diagnosed clinically with dermatophytosis, any age group and any sex
Who cannot join
- Patients under either Local or systemic antifungal treatment
About this study
Official title: Species Identification and Antifungal Susceptibility Testing of Dermatophytes Isolated From Patients Attending Dermatology Outpatient Clinic at Kasr Alainy Hospitals
The aim of the study is to compare the efficiency of broth microdilution versus disk diffusion method for antifungal drug susceptibility testing of the most used drugs in dermatophytosis treatment.
- Conditions
- Dermatophyte Infection
- Being tested
- Antifungal susceptibility testing (AFST)
- Medical subject headings
- Dermatomycoses
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Antifungal susceptibility testing (AFST)Diagnostic test
testing the fungal susceptibility to different drugs
| Study group | Role | What they receive |
|---|---|---|
| Antifungal susceptibility testing (AFST) | Not described Receives: Diagnostic Test: Antifungal susceptibility testing (AFST) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Precent susceptibility to each drug
Measure the area of inhibition zone of the drugs to the fungus on the culture
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Dec 2024
- Study start1 Jun 2025 (estimated)
- Primary completion1 Jul 2025 (estimated)
- Study completion1 Aug 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dermatophyte InfectionStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 42 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hagar El Sayed, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06729216
- Sponsor's protocol ID
- Cutaneous Fungal resistance
- Status last verified
- May 2025
- First submitted
- 8 Dec 2024
- Last updated
- 14 May 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Species Identification and Antifungal Susceptibility Testing of Dermatophytes Isolated From Patients Attending Dermatology Outpatient Clinic at Kasr Alainy Hospitals
- ClinicalTrials.gov ID
- NCT06729216
- Acronym / sponsor ID
- Cutaneous Fungal resistance
- Conditions
- Dermatophyte Infection
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 42 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 1 Jun 2025 (estimated)
- Primary completion
- 1 Jul 2025 (estimated)
- Study completion
- 1 Aug 2025 (estimated)
- First posted
- 11 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to compare the efficiency of broth microdilution versus disk diffusion method for antifungal drug susceptibility testing of the most used drugs in dermatophytosis treatment.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Antifungal susceptibility testing (AFST) | – | Diagnostic Test: Antifungal susceptibility testing (AFST) |
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with dermatophytic skin infection
Key inclusion criteria (1 listed)
- Patients diagnosed clinically with dermatophytosis, any age group and any sex
Key exclusion criteria (1 listed)
- Patients under either Local or systemic antifungal treatment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Antifungal susceptibility testing (AFST)testing the fungal susceptibility to different drugs | Diagnostic test | Antifungal susceptibility testing (AFST) |
Primary outcome
Precent susceptibility to each drug
Time frame: 3 months
Measure the area of inhibition zone of the drugs to the fungus on the culture
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2025.
Related trials for Dermatophyte Infection
RecruitingObservational study
Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis
Not yet recruitingPhase 4
Comparative Efficacy of Luliconazole and Bifonazole Combined With Itraconazole in Dermatophytosis
Tinea Corporis,Tinea Cruris,Tinea Faciei
RecruitingObservational study
In Vitro Susceptibility of Dermatophytes to Terbinafine and Itraconazole: MIC Distributions and Elevated-MIC Isolates in Faisalabad, Pakistan
Dermatophytosis, Tinea Corporis
Active, not recruitingPhase 2
Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides
Localized Skin Lesion, Mycosis Fungoides
Not yet recruiting
Systemic Antifungal Plus Q-Switched Nd:YAG Laser for Onychomycosis
Onychomycosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Dermatophyte Infection, run by Cairo University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 14 May 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Precent susceptibility to each drug (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2025.